Clinical trial
A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)
NCT06264310 is registered in ClinicalTrials.gov with River 2 Renal Corp. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Double-Blind, Placebo-Controlled, Dose Range Finding Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist R2R01 Combined With Standard of Care Versus Standard of Care Alone in Outpatients With Worsening Heart Failure (WHF)
- Lead sponsor
- River 2 Renal Corp.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 1, 2024
- Completion date
- November 25, 2024
- Enrollment
- 33 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
heart failure, worsening heart failure (whf)